This is a working overview of modified GRF(1-29), written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-15. Anything still debated is marked as such rather than presented as settled.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
== Side-effects == The most common side-effects are upper respiratory tract infection, diarrhea, combined edema/peripheral edema and headache, respectively. Most clinical adverse events were similar between groups treated with pioglitazone in combination with metformin and those treated with pioglitazone monotherapy.
Eladocagene exuparvovec, sold under the brand name Upstaza among others, is a gene therapy product for the treatment of aromatic L‑amino acid decarboxylase (AADC) deficiency. It infuses the gene encoding for the human aromatic L-amino acid decarboxylase enzyme into the putamen region of the brain. The subsequent expression of aromatic L-amino acid decarboxylase results in dopamine production and, as a result, development of motor function in people with aromatic L-amino acid decarboxylase deficiency. Eladocagene exuparvovec is an adeno-associated virus vector-based gene therapy. The most common side effects include initial insomnia, irritability and dyskinesia. The most common side effects of eladocagene exuparvovec (Kebilidi) include dyskinesia (involuntary muscle movements), fever, low blood pressure, anemia (low red blood cell count), increased saliva production, insomnia, low levels of potassium, phosphate, and/or magnesium, and procedural complications such as respiratory and cardiac arrest. Eladocagene exuparvovec was approved for medical use in the European Union in July 2022, and in the United States in November 2024.
=== Soviet Union === The Soviet Union was the other major ally of the Việt Minh, alongside the PRC. Moscow supplied GAZ-built trucks, truck engines and motor-parts, fuel, tyres, many different kinds of arms and weapons (including thousands of Škoda-manufactured light machine-guns of Czech origin), all kinds of ammunition (ranging from rifle to machine-gun ammunition), various types of anti-aircraft guns (such as the 37mm air-defense gun) and even cigarettes and tobacco products. During Operation Hirondelle, French Union paratroopers captured and destroyed many tonnes of Soviet-supplied material destined for Việt Minh use in the area of Ky Lua. According to General Giap, the chief military leader of all Việt Minh forces, the Việt Minh used about 400 Soviet-produced GAZ-51 trucks at the Battle of Dien Bien Phu. Because the trucks were concealed and hidden with the use of highly effective camouflage (consisting predominantly of thick vegetation), French Union reconnaissance aircraft were not able to notice them and take note of the effective Việt Minh supply-train. On May 6, 1954, during the siege against French forces at the valley of Dien Bien Phu, Soviet-supplied Katyusha MLRS were successfully fielded against French Union military outposts, destroying enemy troop formations and bases and lowering their morale levels. Together with the PRC, the Soviet Union sent up to 2,000 military advisors to provide training to the Việt Minh guerrilla troops and to turn it into a conventional army.
Sources: en.wikipedia.org
== See also == Artificial Intelligence Act — 2024 European Union regulation Privacy laws of the United States Use of artificial intelligence by the United States Department of Defense Americans for Responsible Innovation - nonprofit advocacy group
=== Origin === Detrital zircons are part of the sediment derived from weathering and erosion of pre-existing rocks. Since zircons are heavy and highly resistant at Earth's surface, many zircons are transported, deposited and preserved as detrital zircon grains in sedimentary rocks.
=== Fleischmann–Pons experiment === The most famous cold fusion claims were made by Stanley Pons and Martin Fleischmann in 1989. After a brief period of interest by the wider scientific community, their reports were called into question by nuclear physicists. Pons and Fleischmann never retracted their claims, but moved their research program from the US to France after the controversy erupted.
=== Pre-release revenue === The film's pre-release rights for Darbar were sold for ₹220 crore (US$23 million). Tamil Nadu theatrical rights of the film were sold for ₹60 crore (US$6.2 million), rights in Kerala were sold for ₹6 crore (US$620,000).
Sources: en.wikipedia.org
=== RMI Training === Remote Medical International provides remote medicine training courses taught by professionally trained and clinically active practitioners. RMI has trained over 13,000 students through public and private training courses including Wilderness First Aid, Wilderness First Responder, Remote Emergency Medical Technician, Remote Medicine for the Advanced Provider, and multiple recertification courses. RMI students include: all branches of the US military, energy companies, US intelligence agencies, law enforcement, FBI, executive protection, border patrol, special operations, national research organizations, National Park and Forest Services, universities, science foundations, guiding services, and individual adventurers.
where dm/dt is the mass dissolution rate, D the diffusion coefficient, A the surface area of solid in contact with the dissolution medium, Cs the saturation solubility, C the bulk concentration, and h the thickness of the unstirred diffusion layer. Because A scales inversely with particle diameter, reducing median diameter from approximately 50 μm to 5 μm increases the available surface area roughly ten-fold and produces a corresponding increase in dissolution rate at constant solubility. At sub-micron diameters, Cs itself increases according to the Ostwald–Freundlich equation, providing an additional thermodynamic contribution to dissolution. Under the Biopharmaceutics Classification System (BCS), drugs are categorized by aqueous solubility and intestinal permeability. Micronization confers the greatest clinical benefit for BCS Class II compounds (low solubility, high permeability), where dissolution rate — not membrane permeation — limits absorption. For BCS Class III and IV compounds, in which permeability is the rate-limiting step, particle size reduction alone produces little change in bioavailability and must be combined with permeation enhancers or alternative delivery strategies.
=== EC 2.6.1: Transaminases === EC 2.6.1.1: aspartate transaminase EC 2.6.1.2: alanine transaminase EC 2.6.1.3: cysteine transaminase EC 2.6.1.4: glycine transaminase EC 2.6.1.5: tyrosine transaminase EC 2.6.1.6: leucine transaminase EC 2.6.1.7: kynurenine—oxoglutarate transaminase EC 2.6.1.8: deleted EC 2.6.1.9: histidinol-phosphate transaminase EC 2.6.1.10: deleted, included with EC 2.6.1.21, D-amino-acid transaminase EC 2.6.1.11: acetylornithine transaminase EC 2.6.1.12: alanine—oxo-acid transaminase EC 2.6.1.13: ornithine aminotransferase EC 2.6.1.14: asparagine—oxo-acid transaminase EC 2.6.1.15: glutamine—pyruvate transaminase EC 2.6.1.16: glutamine—fructose-6-phosphate transaminase (isomerizing) EC 2.6.1.17: succinyldiaminopimelate transaminase EC 2.6.1.18: β-alanine—pyruvate transaminase EC 2.6.1.19: 4-aminobutyrate transaminase EC 2.6.1.20: deleted EC 2.6.1.21: D-amino-acid transaminase EC 2.6.1.22: (S)-3-amino-2-methylpropionate transaminase EC 2.6.1.23: 4-hydroxyglutamate transaminase EC 2.6.1.24: diiodotyrosine transaminase EC 2.6.1.25: deleted, Now included with EC 2.6.1.24 diiodotyrosine transaminase EC 2.6.1.26: thyroid-hormone transaminase EC 2.6.1.27: tryptophan transaminase EC 2.6.1.28: tryptophan—phenylpyruvate transaminase EC 2.6.1.29: diamine transaminase EC 2.6.1.30: pyridoxamine—pyruvate transaminase EC 2.6.1.31: pyridoxamine—oxaloacetate transaminase EC 2.6.1.32: valine—3-methyl-2-oxovalerate transaminase EC 2.6.1.33: dTDP-4-amino-4,6-dideoxy-D-glucose transaminase EC 2.6.1.34: UDP-N-acetylbacillosamine transaminase EC 2.6.1.35: glycine—oxaloacetate transaminase EC 2.6.1.36: L-lysine 6-transaminase EC 2.6.1.37: (2-aminoethyl)phosphonate—pyruvate transaminase EC 2.6.1.38: histidine transaminase EC 2.6.1.39: 2-aminoadipate transaminase EC 2.6.1.40: (R)-3-amino-2-methylpropionate—pyruvate transaminase EC 2.6.1.41: D-methionine—pyruvate transaminase EC 2.6.1.42: branched-chain-amino-acid transaminase EC 2.6.1.43: aminolevulinate transaminase EC 2.6.1.44: alanine—glyoxylate transaminase EC 2.6.1.45: serine—glyoxylate transaminase EC 2.6.1.46: diaminobutyrate—pyruvate transaminase EC 2.6.1.47: alanine—oxomalonate transaminase EC 2.6.1.48: 5-aminovalerate transaminase EC 2.6.1.49: dihydroxyphenylalanine transaminase EC 2.6.1.50: glutamine—scyllo-inositol transaminase EC 2.6.1.51: serine—pyruvate transaminase EC 2.6.1.52: phosphoserine transaminase EC 2.6.1.53: Now EC 1.4.1.13, glutamate synthase (NADPH) EC 2.6.1.54: pyridoxamine-phosphate transaminase EC 2.6.1.55: taurine—2-oxoglutarate transaminase EC 2.6.1.56: 1D-1-guanidino-3-amino-1,3-dideoxy-scyllo-inositol transaminase EC 2.6.1.57: aromatic-amino-acid transaminase EC 2.6.1.58: phenylalanine(histidine) transaminase EC 2.6.1.59: dTDP-4-amino-4,6-dideoxygalactose transaminase EC 2.6.1.60: aromatic-amino-acid—glyoxylate transaminase EC 2.6.1.61: identical to EC 2.6.1.40, (R)-3-amino-2-methylpropionate—pyruvate transaminase EC 2.6.1.62: adenosylmethionine—8-amino-7-oxononanoate transaminase EC 2.6.1.63: kynurenine—glyoxylate transaminase EC 2.6.1.64: glutamine—phenylpyruvate transaminase EC 2.6.1.65: N6-acetyl-β-lysine transaminase EC 2.6.1.66: valine—pyruvate transaminase EC 2.6.1.67: 2-aminohexanoate transaminase EC 2.6.1.68: Now classified as EC 2.6.1.13, ornithine aminotransferase and EC 2.6.1.36, L-lysine 6-transaminase EC 2.6.1.69: identical to EC 2.6.1.11, ((acetylornithine transaminase))|identical to EC 2.6.1.11, acetylornithine transaminase EC 2.6.1.70: aspartate—phenylpyruvate transaminase EC 2.6.1.71: lysine—pyruvate 6-transaminase EC 2.6.1.72: D-4-hydroxyphenylglycine transaminase EC 2.6.1.73: methionine—glyoxylate transaminase EC 2.6.1.74: cephalosporin-C transaminase EC 2.6.1.75: cysteine-conjugate transaminase EC 2.6.1.76: diaminobutyrate—2-oxoglutarate transaminase EC 2.6.1.77: taurine—pyruvate aminotransferase EC 2.6.1.78: aspartate—prephenate aminotransferase EC 2.6.1.79: glutamate—prephenate aminotransferase EC 2.6.1.80: nicotianamine aminotransferase EC 2.6.1.81: succinylornithine transaminase EC 2.6.1.82: putrescine aminotransferase EC 2.6.1.83: LL-diaminopimelate aminotransferase EC 2.6.1.84: arginine—pyruvate transaminase EC 2.6.1.85: aminodeoxychorismate synthase EC 2.6.1.86: 2-amino-4-deoxychorismate synthase EC 2.6.1.87: UDP-4-amino-4-deoxy-L-arabinose aminotransferase EC 2.6.1.88: methionine transaminase EC 2.6.1.89: dTDP-3-amino-3,6-dideoxy-α-D-glucopyranose transaminase EC 2.6.1.90: dTDP-3-amino-3,6-dideoxy-α-D-galactopyranose transaminase EC 2.6.1.91: Identical to EC 2.6.1.34, UDP-N-acetylbacillosamine transaminase EC 2.6.1.92: UDP-4-amino-4,6-dideoxy-N-acetyl-β-L-altrosamine transaminase EC 2.6.1.93: neamine transaminase EC 2.6.1.94: 2′-deamino-2′-hydroxyneamine transaminase EC 2.6.1.95: neomycin C transaminase EC 2.6.1.96: 4-aminobutyrate—pyruvate transaminase EC 2.6.1.97: archaeosine synthase EC 2.6.1.98: UDP-2-acetamido-2-deoxy-ribo-hexuluronate aminotransferase EC 2.6.1.99: L-tryptophan—pyruvate aminotransferase EC 2.6.1.100: L-glutamine:2-deoxy-scyllo-inosose aminotransferase EC 2.6.1.101: L-glutamine:3-amino-2,3-dideoxy-scyllo-inosose aminotransferase EC 2.6.1.102: GDP-perosamine synthase EC 2.6.1.103: (S)-3,5-dihydroxyphenylglycine transaminase EC 2.6.1.104: 3-dehydro-glucose-6-phosphate—glutamate transaminase EC 2.6.1.105: lysine—8-amino-7-oxononanoate transaminase EC 2.6.1.106: dTDP-3-amino-3,4,6-trideoxy-α-D-glucose transaminase EC 2.6.1.107: β-methylphenylalanine transaminase EC 2.6.1.108: (5-formylfuran-3-yl)methyl phosphate transaminase EC 2.6.1.109: 8-amino-3,8-dideoxy-α-D-manno-octulosonate transaminase EC 2.6.1.110: dTDP-4-dehydro-2,3,6-trideoxy-D-glucose 4-aminotransferase EC 2.6.1.111: 3-aminobutanoyl-CoA transaminase EC 2.6.1.112: (S)-ureidoglycine—glyoxylate transaminase EC 2.6.1.113: putrescine—pyruvate transaminase EC 2.6.1.114: 8-demethyl-8-aminoriboflavin-5′-phosphate synthase EC 2.6.1.115: 5-hydroxydodecatetraenal 1-aminotransferase EC 2.6.1.116: 6-aminohexanoate aminotransferase EC 2.6.1.117: L-glutamine—4-(methylsulfanyl)-2-oxobutanoate aminotransferase EC 2.6.1.118: [amino-group carrier protein]-γ-(L-lysyl)-L-glutamate aminotransferase EC 2.6.1.119: vanillin aminotransferase
== Research areas == RCB engages in contemporary research at the interface of disciplines constituting biotechnology in its broadest definition. Research programmes aim to integrate science, engineering, medicine and agriculture in biotechnology and emphasize on their relevance to the regional societies. A broad range of research areas planned include:
=== First representation === A copper vaporizer block is electrically heated with two 100 watt cartridge heaters and a stainless steel capillary allow introduction of sample and consequent partial vaporization. The capillary and the vaporizer block are soldered together to ensure stable thermal contact. The resultant supersonic jet then passes through the ion source for introduction into the quadrupole mass spectrometer.
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.